CD39 transforming cancer therapy by modulating tumor microenvironment

被引：5
作者：
Xu, Suling [1 ]
Ma, Yuhan [1 ]
Jiang, Xinyu [1 ]
Wang, Qingqing [2 ]
Ma, Wenxue [3 ,4 ]
机构：
[1] Ningbo Univ, Affiliated Hosp 1, Dept Dermatol, Sch Med, Ningbo 315020, Zhejiang, Peoples R China
[2] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China
[3] Univ Calif San Diego, Sanford Stem Cell Inst, Dept Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
来源：
CANCER LETTERS | 2024年 / 597卷
关键词：
CD39; Tumor Microenvironment (TME); Immunoregulation; Angiogenesis; Metabolic reprogramming; Therapeutic targets; EXPRESSION; PROGNOSIS; SURFACE;
D O I：
10.1016/j.canlet.2024.217072
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.
引用
收藏
页数：11
相关论文
共 110 条
[11]   CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations? [J].
Battastini, Ana Maria Oliveira ;
Figueiro, Fabricio ;
Leal, Daniela Bitencourt Rosa ;
Doleski, Pedro Henrique ;
Schetinger, Maria Rosa Chitolina .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[12]  
Battesti Gilles, 2024, Skin Health Dis, V4, pe334, DOI [10.1002/ski2.334, 10.1002/ski2.334]
[13]   The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition [J].
Bauer, Arthur ;
Gebauer, Niklas ;
Knief, Juliana ;
Tharun, Lars ;
Arnold, Nele ;
Riecke, Armin ;
Steinestel, Konrad ;
Witte, Hanno M. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) :3193-3208
[14]   Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection [J].
Cai, Xiao-Yan ;
Ni, Xiao-Chun ;
Yi, Yong ;
He, Hong-Wei ;
Wang, Jia-Xing ;
Fu, Yi-Peng ;
Sun, Jian ;
Zhou, Jian ;
Cheng, Yun-Feng ;
Jin, Jian-Jun ;
Fan, Jia ;
Qiu, Shuang-Jian .
MEDICINE, 2016, 95 (40)
[15]  
Cai XY, 2015, INT J CLIN EXP PATHO, V8, P14757
[16]   CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells [J].
Canale, Fernando P. ;
Ramello, Maria C. ;
Nunez, Nicolas ;
Furlan, Cintia L. Araujo ;
Bossio, Sabrina N. ;
Serran, Melisa Gorosito ;
Boari, Jimena Tosello ;
del Castillo, Andres ;
Ledesma, Marta ;
Sedlik, Christine ;
Piaggio, Eliane ;
Gruppi, Adriana ;
Rodriguez, Eva V. Acosta ;
Montes, Carolina L. .
CANCER RESEARCH, 2018, 78 (01) :115-128
[17]  
Canale Fernando Pablo, 2018, Oncoscience, V5, P65, DOI [10.18632/oncoscience.404, 10.18632/oncoscience.404]
[18]   Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy [J].
Chen, Qiuqiang ;
Guo, Xuejun ;
Ma, Wenxue .
ONCOLOGY RESEARCH, 2024, 32 (01) :49-60
[19]   CD39: the potential target in small cell lung cancer [J].
Chen, Shanhao ;
Wu, Shengyu ;
Zhang, Liping ;
Zhang, Wei ;
Liu, Yu ;
Chen, Bin ;
Zhao, Sha ;
Li, Wei ;
Sun, Chenglong ;
Wang, Lei ;
Jia, Keyi ;
Wang, Hao ;
Chen, Peixin ;
Wu, Chunyan ;
Zhu, Junjie ;
He, Yayi ;
Zhou, Caicun .
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) :1483-+
[20]   Immune profiling identifies CD8+ T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer [J].
Chen, Zhen ;
Guo, Meng-Li ;
Li, Ya-Yi ;
Yan, Kai ;
Li, Liang ;
Shen, Fei ;
Guan, Haixia ;
Liu, Qing-Zhi ;
Xu, Bo ;
Lian, Zhe-Xiong .
FRONTIERS IN IMMUNOLOGY, 2022, 13
12345678910